Compare NTLA & SLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | SLDP |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Electrical Products |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.9M | 876.8M |
| IPO Year | 2016 | N/A |
| Metric | NTLA | SLDP |
|---|---|---|
| Price | $10.75 | $5.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 1 |
| Target Price | ★ $19.83 | $7.00 |
| AVG Volume (30 Days) | 3.6M | ★ 5.8M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,528,000.00 | $19,802,000.00 |
| Revenue This Year | $1.96 | $27.38 |
| Revenue Next Year | N/A | $36.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.52 | 9.85 |
| 52 Week Low | $5.90 | $0.68 |
| 52 Week High | $28.25 | $8.86 |
| Indicator | NTLA | SLDP |
|---|---|---|
| Relative Strength Index (RSI) | 61.75 | 57.76 |
| Support Level | $8.94 | $4.82 |
| Resistance Level | $9.62 | $5.47 |
| Average True Range (ATR) | 0.46 | 0.27 |
| MACD | 0.28 | 0.13 |
| Stochastic Oscillator | 89.42 | 87.92 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.